Swiss National Bank Has $934,000 Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Swiss National Bank grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,000 shares of the company’s stock after acquiring an additional 2,700 shares during the period. Swiss National Bank owned 0.15% of Keros Therapeutics worth $934,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. AlphaQuest LLC lifted its position in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics during the fourth quarter worth about $99,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after acquiring an additional 1,372 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Keros Therapeutics in the third quarter valued at about $216,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

KROS has been the topic of a number of research reports. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Scotiabank dropped their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Finally, HC Wainwright dropped their price target on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Stock Down 1.8 %

Keros Therapeutics stock opened at $10.79 on Friday. Keros Therapeutics, Inc. has a 52 week low of $9.78 and a 52 week high of $72.37. The company’s 50 day moving average price is $11.15 and its two-hundred day moving average price is $34.44. The stock has a market cap of $437.66 million, a P/E ratio of -2.07 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.